In order to prevent severe hypersensitivity reactions, all patients must be carried out using premedication with corticosteroids, antihistamines and H2 histamine receptor antagonists. For example, 20 mg dexamethasone (or its equivalent) into approximately 12 and 6 hours prior to administration of the drug testosterone enanthate vs propionate, 50 mg diphenhydramine (or its equivalent) intravenously and cimetidine 300 mg or ranitidine 50 mg intravenously 30-60 minutes prior to the introduction.
When you select and dose in each individual case should be guided by the data of literature.
The recommended dose of for the treatment of Kaposi’s sarcoma in patients with AIDS is 100 mg / m² in the form of 3- hour infusion every 2 weeks.
the introduction of the drug not to be repeated until neutrophil not be at least 1500 / ml blood, and platelet count of at least 100,000 / microliter blood. Patients who after observed severe neutropenia (neutrophil count <500 / blood mm³ for 7 days or longer period of time) or severe peripheral neuropathy during subsequent courses of treatment should be reduced by 20% .
a solution formulation is prepared immediately prior to administration by diluting a concentrate of 0.9% sodium chloride or 5% dextrose, or 5% dextrose in 0.9% sodium chloride solution for injection or 5% dextrose in Ringer’s solution to a final concentration of from 0.3 to 1.2 mg / ml. Opalescent solutions may be prepared for the composition present in the dosage form of the carrier bases, and after filtration the solution opalescence persists.
In the preparation, storage and administration necessary to use equipment which does not contain parts of PVC. should be administered through the system with a built-membrane filter (pore size less than 0.22 micron).
The frequency and severity of side effects are dose-dependent. From the side of hematopoiesis: neutropenia, thrombocytopenia, anemia. Bone marrow suppression, primarily granulocytic germ, has been a major toxic effect of limiting the dose. The maximum decrease in neutrophils is usually observed on the day of 8-11, the normalization occurs on day 22. Allergic reactions: in the first hours after administration may experience hypersensitivity reactions manifested by bronchospasm, decreased blood pressure, pain in the chest, a rush of blood to the face, skin rash, generalized urticaria, angioedema. described isolated cases of fever and back pain.
Since the cardiovascular system: blood pressure, rarely – increased blood pressure, bradycardia, may be tachycardia, atrioventricular block, ECG changes, thrombosis and thrombophlebitis. The respiratory system: interstitial pneumonia, lung fibrosis, pulmonary embolism, as well as more frequent development of radiation pneumonitis in patients while undergoing radiation therapy. from the nervous system: mainly paresthesia. Rarely – seizures type grand mal, visual disturbances, ataxia, encephalopathy, autonomic testosterone enanthate vs propionate neuropathy, manifested paralytic ileus and orthostatic hypotension.
From the Musculoskeletal System: arthralgia, myalgia. From the digestive system: nausea, vomiting, diarrhea, mucositis, anorexia, constipation. Individual reports of acute intestinal obstruction, intestinal perforation, mesenteric artery thrombosis, ischemic colitis. Liver function: increased activity of “liver” transaminases (often ACT), alkaline phosphatase, and bilirubin in blood serum. Cases of gepatonekroz and hepatic encephalopathy. Local reactions: pain, swelling, erythema, induration and pigmentation of the skin at the injection site; extravasation can cause inflammation and necrosis of the subcutaneous tissue. From the side of the track and skin appendages: alopecia, rarely violation of pigmentation or discoloration of the nail bed. Other side effects:asthenia and malaise
Symptoms: bone marrow aplasia, peripheral neuropathy, mucositis. Treatment: symptomatic. Antidote paclitaxel is not known.
Interaction with other drugs
Cisplatin reduces total clearance of paclitaxel by 20% (the more severe myelosuppression observed when paclitaxel is administered after cisplatin).
Co-administration with cimetidine, ranitidine, dexamethasone or diphenhydramine does not affect the relationship of paclitaxel to plasma proteins.
The inhibitors of microsomal oxidation ( including ketoconazole, cimetidine, verapamil, diazepam, quinidine, cyclosporin, etc.) inhibit the metabolism of paclitaxel.
Application of should be administered under the supervision of a physician who has experience with anticancer chemotherapeutic agents.
In order to prevent severe hypersensitivity reactions, all patients must be conducted premedication with corticosteroids, antihistamines and antagonists of H2 histamine receptors: 20 mg of dexamethasone (or equivalent) into approximately 12 and 6 hours , 50 mg diphenhydramine (or its equivalent) intravenously and cimetidine 300 mg or ranitidine 50 mg intravenously 30-60 minutes prior .
In the case of severe hypersensitivity reactions infusion of the drug should be discontinued immediately and symptomatic treatment start, and re-inject the drug should not be.
The polyoxyethylated castor oil, which is part of the drug , may cause extraction DEGP [di- (2-hexyl) phthalate] from plasticised polyvinyl chloride (PVC) containers, where the degree of leaching DEGP increases with increasing solution concentration and with time. Therefore, the preparation, storage and administrationtestosterone enanthate vs propionate® should use equipment that does not contain any parts made of PVC.
During treatment should be regularly monitored picture peripheral blood, blood pressure, heart rate and the number of breaths (particularly during the first hour of infusion), ECG -control (and prior to treatment).
in cases of atrioventricular conduction disturbances, after repeated administration necessary to carry out continuous cardiac monitoring.
If is used in combination with cisplatin, you must first enter the , followed by cisplatin.
Patients during treatment with and for at least 3 months after completion of therapy should use reliable methods of contraception.
in the period of treatment should refrain from activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
in one bottle with instructions for use in a pile of cardboard.
1 bottle with instructions for use in a pile of cardboard, in the completion of the infusion system with built-in membrane filter with a pore diameter of not more than 0.22. does not contain parts of PVC.
By 30, 50, 72 or 100 vials with an equal number of instructions for use tossed into a box made of cardboard (for hospitals).
At 30, 50, 72 or 100 vials in configuration with an equal amount of infusion systems with integrated membrane filter with pore diameters of not more than 0.22, not containing parts of PVC and with equal amounts of the instructions testosterone enanthate vs propionate for use of the cardboard box (for hospitals).